Physician
Infectious Disease
Dr. Arthur M. Friedlander, MD
|
|
Give Review
Dr. Arthur M. Friedlander is an expert in the field of Infectious Disease. He went to University of Pittsburgh School of Medicine. Arthur M. Friedlander is also published. He has 99 publications published. The lastest publication: "Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigen.'
Publications
- Erratum for Jelacic et al., Exposure to Bacillus anthracis Capsule Results in Suppression of Human Monocyte-Derived Dendritic Cells.
- A Reaction Path Study of the Catalysis and Inhibition of the Bacillus anthracis CapD γ-Glutamyl Transpeptidase.
- Exposure to Bacillus anthracis capsule results in suppression of human monocyte-derived dendritic cells.
- Genome Sequence of the Attenuated Carbosap Vaccine Strain of Bacillus anthracis.
- Military vaccines in today's environment.
- Probing the Substrate and Acceptor Specificity of the ?-Glutamyltranspeptidase.
- Efficacy of a capsule conjugate vaccine against inhalational anthrax in rabbits and monkeys.
- Improvement of a potential anthrax therapeutic by computational protein design.
- Human transferrin confers serum resistance against Bacillus anthracis.
- A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics.
- Treatment of experimental anthrax with recombinant capsule depolymerase.
- Bacillus anthracis spores of the bclA mutant exhibit increased adherence to epithelial cells, fibroblasts, and endothelial cells but not to macrophages.
- Microarray analysis of transposon insertion mutations in Bacillus anthracis: global identification of genes required for sporulation and germination.
- Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis.
- Anthrax lethal toxin impairs innate immune functions of alveolar macrophages and facilitates Bacillus anthracis survival.
- Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax.
- Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrop...
- Recombinant F1-V fusion protein protects black-footed ferrets (Mustela nigripes) against virulent Yersinia pestis infection.
- Needle-free skin patch vaccination method for anthrax.
- Cellular immunity in pyelonephritis: identification of suppressor cell activity of spleen cells in response to concanavalin A and inhibition of lymphocyte-mediated L c...
- Production of bladder stones by human T mycoplasmas.
- DNA release as a direct measure of microbial killing by phagocytes.
- Experimental prostatitis: relationship to pyelonephritis.
- Clinical recognition and management of patients exposed to biological warfare agents.
- Diversity in a variable-number tandem repeat from Yersinia pestis.
- Tackling anthrax.
- Effects of anthrax toxin components on human neutrophils.
- An attenuated strain of Bacillus anthracis (CDC 684) has a large chromosomal inversion and altered growth kinetics.
- Anthrax: clinical features, pathogenesis, and potential biological warfare threat.
- Inhibition of mouse peritoneal macrophage DNA synthesis by infection with the arenavirus Pichinde.
- Weak anamnestic responses of inbred mice to Yersinia F1 genetic vaccine are overcome by boosting with F1 polypeptide while outbred mice remain nonresponsive.
- Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process.
- Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.
- Characterization of a Bacillus anthracis spore coat-surface protein that influences coat-surface morphology.
- Pathology of experimental inhalation anthrax in the rhesus monkey.
- Serum concentrations of penicillin, doxycycline, and ciprofloxacin during prolonged therapy in rhesus monkeys.
- Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.
- Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-D-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based co...
- In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody.
- Anthrax edema toxin differentially regulates lipopolysaccharide-induced monocyte production of tumor necrosis factor alpha and interleukin-6 by increasing intracellula...
- Bacterial filamentation of Yersinia pestis by beta-lactam antibiotics in experimentally infected mice.
- Characterization of macrophage sensitivity and resistance to anthrax lethal toxin.
- Genome-based bioinformatic selection of chromosomal Bacillus anthracis putative vaccine candidates coupled with proteomic identification of surface-associated antigens.
- Morphogenesis of the Bacillus anthracis spore.
- Anthrax lethal factor inhibition.
- Processing, assembly and localization of a Bacillus anthracis spore protein.
- Pathology of experimental pneumonic plague produced by fraction 1-positive and fraction 1-negative Yersinia pestis in African green monkeys (Cercopithecus aethiops).
- Anthrax as a potential biological warfare agent.
- Tularemia as a biological weapon: medical and public health management.
- Anthrax vaccine: short-term safety experience in humans.
- Calcium is required for the expression of anthrax lethal toxin activity in the macrophagelike cell line J774A.1.
- Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigen.
- Protein synthesis is required for expression of anthrax lethal toxin cytotoxicity.
- Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis.
- Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice.
- Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine.
- Localization and assembly of proteins comprising the outer structures of the Bacillus anthracis spore.
- The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation.
- Macrophage-derived cell lines do not express proinflammatory cytokines after exposure to Bacillus anthracis lethal toxin.
- Anthrax vaccines.
- Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis.
- Structure-function analysis of Bacillus anthracis edema factor by using monoclonal antibodies.
- Internalization and processing of Bacillus anthracis lethal toxin by toxin-sensitive and -resistant cells.
- Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice.
- Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mous...
- Antibiotic treatment of experimental pneumonic plague in mice.
- Association of Bacillus anthracis capsule with lethal toxin during experimental infection.
- Anti-V antigen antibody protects macrophages from Yersinia pestis -induced cell death and promotes phagocytosis.
- Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits.
- V antigen of Yersinia pestis inhibits neutrophil chemotaxis.
- Analysis of the Yersinia pestis V protein for the presence of linear antibody epitopes.
- Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.
- Studies on the role of plasminogen activator in systemic infection by virulent Yersinia pestis strain C092.
- Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.
- Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies.
- Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs.
- Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge.
- Postexposure prophylaxis against experimental inhalation anthrax.
- Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis.
- Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin.
- Functional characterization of protease-treated Bacillus anthracis protective antigen.
- In vitro correlate of immunity in a rabbit model of inhalational anthrax.
- The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.
- Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin.
- Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans.
- Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax.
- Immune response to Yersinia outer proteins and other Yersinia pestis antigens after experimental plague infection in mice.
- Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestis.
- Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques.
- Anthrax as a biological weapon, 2002: updated recommendations for management.
- Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid.
- Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans.
- Construction of a rhamnose mutation in Bacillus anthracis affects adherence to macrophages but not virulence in guinea pigs.
- Anthrax capsule vaccine protects against experimental infection.
- The NheA component of the non-hemolytic enterotoxin of Bacillus cereus is produced by Bacillus anthracis but is not required for virulence.
- The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.
- The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria.
- ClpX contributes to innate defense peptide resistance and virulence phenotypes of Bacillus anthracis.
Schools
University of Pittsburgh Main Campus
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Education
-
SUNY Health Science Center at Brooklyn -
University of Pittsburgh School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Tuan M. Tran, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Henry Neumann, MD |
|
|
Dr. Janice M. Rusnak, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert G. Rivard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anusha Belani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James W. Martin Jr., MD |
|
|
Dr. James M. Veazey Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bret K. Purcell, MD
This Doctor is OpenDoctor Recommended.
|